Clinical Trials Browser

Phase 1/2 × Glioblastoma × cabozantinib × Clear all

NCT05039281 2025-12-19

Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma

Phase 1/2 Recruiting

Glioblastoma, Gliosarcoma